Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 May;96(5):720-8.
doi: 10.3324/haematol.2010.034264. Epub 2011 Feb 17.

Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project

Rafael Marcos-Gragera  1 , Claudia Allemani, Carmen Tereanu, Roberta De Angelis, Riccardo Capocaccia, Marc Maynadie, Stefano Luminari, Stefano Ferretti, Tom Børge Johannesen, Risto Sankila, Marja-Liisa Karjalainen-Lindsberg, Arianna Simonetti, Maria Carmen Martos, Martine Raphaël, Pilar Giraldo, Milena Sant; HAEMACARE Working Group
Collaborators, Affiliations

Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project

Rafael Marcos-Gragera et al. Haematologica. 2011 May.

Abstract

Background: The European Cancer Registry-based project on hematologic malignancies (HAEMACARE), set up to improve the availability and standardization of data on hematologic malignancies in Europe, used the European Cancer Registry-based project on survival and care of cancer patients (EUROCARE-4) database to produce a new grouping of hematologic neoplasms (defined by the International Classification of Diseases for Oncology, Third Edition and the 2001/2008 World Health Organization classifications) for epidemiological and public health purposes. We analyzed survival for lymphoid neoplasms in Europe by disease group, comparing survival between different European regions by age and sex.

Design and methods: Incident neoplasms recorded between 1995 to 2002 in 48 population-based cancer registries in 20 countries participating in EUROCARE-4 were analyzed. The period approach was used to estimate 5-year relative survival rates for patients diagnosed in 2000-2002, who did not have 5 years of follow up.

Results: The 5-year relative survival rate was 57% overall but varied markedly between the defined groups. Variation in survival within the groups was relatively limited across European regions and less than in previous years. Survival differences between men and women were small. The relative survival for patients with all lymphoid neoplasms decreased substantially after the age of 50. The proportion of 'not otherwise specified' diagnoses increased with advancing age.

Conclusions: This is the first study to analyze survival of patients with lymphoid neoplasms, divided into groups characterized by similar epidemiological and clinical characteristics, providing a benchmark for more detailed analyses. This Europe-wide study suggests that previously noted differences in survival between regions have tended to decrease. The survival of patients with all neoplasms decreased markedly with age, while the proportion of 'not otherwise specified' diagnoses increased with advancing age. Thus the quality of diagnostic work-up and care decreased with age, suggesting that older patients may not be receiving optimal treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Sex-specific period estimates of 5-year relative survival for patients with lymphoid neoplasms diagnosed in 2000–2002 and grouped according to HAEMACARE.
Figure 2.
Figure 2.
European region-specific period estimates of 5-year relative survival of patients with lymphoid malignancies diagnosed in 2000–2002, and grouped according to HAEMACARE.
See this image and copyright information in PMC

References

    1. Jaffe ES, Harris NL, Stein H, Vardiman J, editors. World Health Organisation Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
    1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107 (1):265–76. - PMC - PubMed
    1. National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. Cancer. 1982;49(10):2112–35. - PubMed
    1. Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1(8580):292–3. - PubMed
    1. Lukes RJ, Collins RD. Immunologic characterization of human malignant lymphomas. Cancer. 1974;34(4 Suppl):1488–503. - PubMed

Publication types

MeSH terms